Back to Search
Start Over
Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study
- Source :
- Anatolian Journal of Cardiology, Vol 25, Iss 10, Pp 721-732 (2021), Anatolian Journal of Cardiology, Anatol J Cardiol
- Publication Year :
- 2021
- Publisher :
- KARE Publishing, 2021.
-
Abstract
- Objective: to evaluate clinical efficacy, safety and tolerability of long-term inhaled iloprost treatment in the daily practice for the management of pulmonary arterial hypertension (PAH). Methods: a total of 115 patients with PAH on inhaled iloprost treatment were included. New York Heart Association (NYHA) functional class, brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and 6-minute walk distance (6MWD) were recorded at baseline and at 3rd to 24th month visits. Safety and tolerability of iloprost treatment were also evaluated during follow-up, as were the survival, clinical worsening, and the related risk factors. Results: the treatment was associated with an increase in the percentage NYHA functional class II (from 0.0% at enrolment to 36.2% at 24th month visit) patients but no significant difference was noted in 6MWD values. Clinical worsening was observed in 63.5% patients, while survival rate was 69.6%. NT-proBNP levels were significantly higher in non-survivors than in survivors (p=0.042). Cox regression analysis revealed the association of female sex [odds ratio (OR)=0.318; 95% confidence interval (CI), 0.128-0.792; p=0.014] and scleroderma-related PAH (OR=0.347; 95% CI, 0.140-0.860; p=0.022) with significantly lower risk (3.14 fold and 2.88 fold, respectively) of mortality. Conclusion: our findings indicate favorable efficacy, safety, and tolerability of long-term iloprost treatment in the management of PAH, whereas improved NYHA functional class was not accompanied with a significant change in 6MWD values. Patient age was a risk factor for clinical worsening, while female sex, scleroderma subtype, and lower NT-proBNP levels were associated with significantly lower mortality risk.<br />Bayer Türk
- Subjects :
- safety
Targeted Drugs
medicine.medical_specialty
medicine.drug_class
Hypertension, Pulmonary
Lower risk
survival
Insights
Prostacyclin
Pulmonary arterial hypertension
Iloprost
Treatment outcome
Safety
Survival
Oral Sildenafil
pulmonary arterial hypertension
Internal medicine
medicine
Natriuretic peptide
Humans
Cardiac and cardiovascular systems
Diseases of the circulatory (Cardiovascular) system
Prospective Studies
Risk factor
iloprost
Survival rate
Original Investigation
Pulmonary Arterial Hypertension
Combination Therapy
business.industry
Odds ratio
Metaanalysis
Brain natriuretic peptide
Nitric-Oxide
Treatment Outcome
Tolerability
RC666-701
treatment outcome
Female
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 21492271 and 21492263
- Volume :
- 25
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Anatolian Journal of Cardiology
- Accession number :
- edsair.doi.dedup.....bd15c9459e6d4f3f5263f04e3b0d58fa